Vaxil Bio Ltd. (TSXV:VXL)
Canada
· Delayed Price · Currency is CAD 0.160
0.00 (0.00%)
At close: Mar 6, 2026
Vaxil Bio Company Description
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer.
Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma.
The company is headquartered in Toronto, Canada.
Vaxil Bio Ltd.
| Country | Canada |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Gadi Levin |
Contact Details
Address: 559 Briar Hill Avenue Toronto, ON M5N 1N1 Canada | |
| Phone | 647-558-5564 |
Stock Details
| Ticker Symbol | VXL |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA92243L1076 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Executive Officer and Chairman |
| Alan Mark Rootenberg B.Com., B.Comm, C.A., C.P.A. | Chief Financial Officer |
| Dr. Riva Kovjazin M.D. | Senior Scientist and Member of Scientific Advisory Board |